This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Actelion Pharmaceuticals Ltd. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Innovations in Pulmonary Arterial Hypertension Treatment by Alessandro Maresta
Introduction
Alessandro Maresta is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of medicine, particularly in the treatment of pulmonary arterial hypertension (PAH). His innovative approaches aim to improve patient outcomes and reduce disease progression.
Latest Patents
Maresta holds a patent for "Methods of treating pulmonary arterial hypertension." This patent describes methods for reducing the risk of disease progression in patients with PAH. The approach involves administering an initial triple combination therapy that includes an endothelin receptor antagonist (ERA), a phosphodiesterase type 5 (PDE-5) inhibitor, and a prostacyclin receptor agonist (IP receptor agonist). This innovative treatment strategy has the potential to significantly enhance the management of PAH.
Career Highlights
Alessandro Maresta is associated with Actelion Pharmaceuticals Ltd., a company renowned for its focus on innovative treatments for pulmonary diseases. His work at Actelion has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Maresta has worked alongside his coworker, Loïc Perchenet, to advance research and development in the treatment of pulmonary arterial hypertension. Their collaboration exemplifies the importance of teamwork in driving innovation in healthcare.
Conclusion
Alessandro Maresta's contributions to the treatment of pulmonary arterial hypertension through his patented methods highlight the critical role of innovation in medicine. His work continues to pave the way for improved therapies and better patient care.